PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 2004Journal of Veterinary Internal Medicine193 citationsOpen Access

Cardiac Troponin-I Concentration in Dogs with Cardiac Disease

View Full Paper
MOMark A. OyamaDSD. David Sisson

Structured PICO

Does plasma cTnI concentration correlate with the presence and severity of cardiac disease in dogs?

P
Population
269 dogs, including 176 healthy dogs and dogs with acquired or congenital heart disease (26 with cardiomyopathy [CM], 37 with degenerative mitral valve disease [MVD], and 30 with subvalvular aortic stenosis [SAS]).
I
Intervention
Plasma cardiac troponin-I (cTnI) measurement using a human immunoassay system
C
Comparator
Healthy dogs (n=176)
O
Outcome
Plasma cTnI concentrationsurrogate

Plasma cTnI is elevated in dogs with cardiac disease and correlates with heart size and survival, suggesting its utility as a biomarker in veterinary cardiology.

Abstract

Cardiac troponin-I (cTnI) is a highly sensitive and specific marker of myocardial injury and can be detected in plasma by immunoassay techniques. The purpose of this study was to establish a reference range for plasma cTnI in a population of healthy dogs using a human immunoassay system and to determine whether plasma cTnI concentrations were high in dogs with acquired or congenital heart disease, specifically cardiomyopathy (CM), degenerative mitral valve disease (MVD), and subvalvular aortic stenosis (SAS). In total, 269 dogs were examined by physical examination, electrocardiography, echocardiography, and plasma cTnI assay. In 176 healthy dogs, median cTnI was 0.03 ng/mL (upper 95th percentile = 0.11 ng/mL). Compared with the healthy population, median plasma cTnI was increased in dogs with CM (0.14 ng/mL; range, 0.03-1.88 ng/mL; P 0.20 ng/mL was significantly shorter than median survival time of those with cTnI <0.20 ng/mL (112 days versus 357 days; P = .006). Plasma cTnI is high in dogs with cardiac disease, correlates with heart size and survival, and can be used as a blood-based biomarker of cardiac disease.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Oyama et al. (2004) studied this question.

synapsesocial.com/papers/6a8196acf34fcd4e77776195https://doi.org/10.1892/0891-6640(2004)18<831:ctcidw>2.0.co;2
Ask AI
Helpful
Bookmark
Share
View Full Paper